



Pioneering α -IL-18 approaches for Innovative therapeutics in severe Inflammatory disorders

Company presentation

MARCH 2026

Forward-Looking Statements

This presentation includes forward-looking statements regarding the development, activity, therapeutic potential and safety of Tadekinig alfa (“IL-18 Binding Protein” or “IL-18BP”). Any statement describing AB2 Bio’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as AB2 Bio’s goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. AB2 Bio’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although AB2 Bio’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by AB2 Bio. As a result, you are cautioned not to rely on these forward-looking statements.

Pursuing path of pioneering treatments for IL-18-opathies with innovative molecule, breakthrough science and strong momentum



- Founded in 2010
- HQs in Lausanne, CH
- Raised > 70 Mio CHF


Eduardo Schiffrin, M.D.
Medical Director



Djordje Filipovic, Ph.D.
Chief Executive Officer




Zoltán Czigler
Chief Financial Officer



Strategic Focus on solutions for IL-18 driven diseases & conditions

IL-18 constitutively expressed in range of non-hematopoietic cells and tightly controlled by IL-18 BP


Medical Need



Dysregulation can cause potentially fatal autoimmune or inflammatory diseases

IL-18 dependence


Tadekinig alfa: “Human” protein for physiological solution to diseases & conditions driven by high IL-18 levels



Tadekinig alfa in uncontrolled pediatric patients regularly relapsing despite being treated with a range of concomitant therapies

Totality


Consistency




Impactful totality of clinical data provides substantial evidence of effectiveness

Strong response to therapy with statistically significant reduction of disease activity, IL-18 levels and improvement of patient activity levels compared to study initiation


Disease activity



Patient activity impact



IL-18 levels




Patient counts below graph: by visit data including unscheduled visits in the respective visit window


Error bars indicate standard error; *p<0.05 = significant, **p<0.01 = very significant, ***p<0.001 = highly significant, ****p<0.0001 = extremely significant

Abbreviations: mAIDAI = Modified Autoinflammatory Disease Activity Index, PGA = Physician Global Assessment

Clinical superiority of Tadekinig alfa over placebo demonstrated by time to disease reactivation, and absence of steroid interventions




No disease reactivations on Tadekinig-alfa treatment




50% of Disease Reactivations on Placebo require emergency steroid intervention

Consistency of results across range of clinical and biomarker parameters in all phases of the clinical investigation



Abbreviations: SAOL = single arm open-label, RW = randomized withdrawal, OLE = open-label extension, mAIDAI = Modified Autoinflammatory Disease Activity Index, PGA = Physician Global Assessment, DR = disease reactivation


Disease activity (mAIDAI)



Steroid dose




IL-18



PGA



Caregiver assessment



Published patient experience exemplifies power of Tadekinig alfa



Patient Disease history

“Hospital” Life



“Side-effect” Life

Normalization



Return to Regular Life

Next best opportunities postulated by top Medical Experts and supported by initial data

Scientific pull to areas of major medical need

„Correcting IL-18/IL-18BP imbalance with Tadekinig alfa is a rational strategy for **treatment of SJIA (MAS)**„

Scott Canna, Alexei Grom, Cem Gabay and others

„Tadekinig alfa is a specific antidote that may increase safety and extend the reach of CAR-T cells for leukemia and beyond blood cancers, Tadekinig alfa has the potential to **increase the efficacy of CAR-T in other cancers**“

Carl June


RHEUMATOLOGY
Concise report

IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome

Shima Yasin¹, Ndate Fall¹, Rachel A. Brown¹, Maggie Henderlight¹, Scott W. Canna², Charlotte Girard-Guyonvarc'h², Cem Gabay², Alexei A. Grom¹ and Grant S. Schulert¹

Rheumatology 2020;59:361-366
doi:10.1093/rheumatology/kez282
Advance Access publication 20 July 2019

MAS Prone SJIA patients



CART: Atologous T cells that are modified to express the chimeric antigen receptor (CAR) targeting specific (malignant) cells.
ICANS: immune effector cell-associated neurotoxicity syndrome

CAR-T

Repeatedly stated focus on (ultra)-rare diseases while management and resourcing volatility remaining

**Priority Review Voucher
regulation extended**

RDEP initiative
Rare Disease Evidence
Principles

**Commissioner launched
Plausible Mechanism
Framework**

De-risked paradigm-changing asset with clear path to first BLA

Strong Foundation

Innovative molecule with unique MoA and Breakthrough Therapy designation

No treatment options or consensus guidelines in lead indication with high unmet medical need

Proprietary IL-18 assay supports addressing other IL-18-opathies with market of \$1.5B

Recent achievements establish value inflection point for AB2 Bio

Impactful Phase 3 data with positive primary endpoint

Successful FDA meeting confirms potential for BLA review

Compelling IL-18 patient data confirm mechanistic hypothesis

Regulatory manufacturing campaigns ready to be executed at WuXi

Partnership with NS confirms strategic value and calibrates commercial value of the asset

US environment outlook for ultra-rare diseases dramatically improving

“AB2 Bio signed 600 million agreement with Nippon Shinyaku”

**Strategic
value
established**

SCRIP
CITELINE COMMERCIAL

Scrip >> Business >> Deals

Switzerland's AB2 Bio Bags Nippon Shinyaku As Late-Stage IL-18 Inhibitor Partner

27 Jan 2025 • By [Kevin Grogan](#)

CEO Djordje Filipovic tells Scrip that after talks with “multiple other potential partners,” the firm chose the Japanese group for its expertise and marketing capabilities in rare diseases” to be the licensing partner for tadekinig alfa in the US.

**Asset
value
calibrated**



In a nutshell

FIRST

**IL-18 targeting
therapy to complete
Phase 3 and proceed
to regulatory
approval**

Tadekinig alfa

ONLY

**physiological
approach to treating
IL-18-driven
diseases and
conditions**

**Pipeline-in-a-product
with potential to change treatment paradigms in immunology and oncology**

Thank you!